# Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

> **NCT02719574** · PHASE1,PHASE2 · COMPLETED · sponsor: **Forma Therapeutics, Inc.** · enrollment: 336 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** FT-2102 (olutasidenib)
- **DRUG:** Azacitidine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT02719574
- **Lead sponsor:** Forma Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-30
- **Primary completion:** 2023-12-28
- **Final completion:** 2024-01-24
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02719574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02719574, "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02719574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*